The coronavirus vaccine developed by laboratories Pfizer and BioNTech is “effective” against the variant Omicron after “three doses” they reported yesterday.
In addition, they want to prepare an immunizer more adapted to this alteration of the virus for March.
According to Albert Bourla, president of Pfizer, two doses offer protection against Omicron and prevent the development of severe disease, but it is clear that the help “improves” with a third injection.
The blood of those who received their third booster dose a month ago neutralized the new variant as effectively as two vaccines fighting the original virus.
The findings are consistent with a preliminary study published by scientists at the African Health Research Institute, which says that Omicron may partially evade the protection of two doses of the Pfizer / BioNTech vaccine and also suggests that a third injection might help.
However, an analysis from the university hospital in Frankfurt, Germany, found a reduced antibody response to Omicron even after three doses.
For its part, the WHO indicated that the new variant appears to have a higher reinfection rate, but causes milder symptoms, although “it is still too early to be sure.”
THE FDA AUTHORIZES THERAPY
The Food and Drug Administration (FDA) of the US approved the emergency use of an AstraZeneca drug to prevent the spread of COVID for those who due to their medical condition cannot get a vaccine.
This product is only authorized for people who are not infected or exposed, who have an immune system that does not allow them to be vaccinated or a history of adverse reactions to it.
It was called Evusheld, it consists of a combination of two monoclonal antibodies and is administered in two consecutive injections, one per antibody.
It is indicated for certain adults and patients over 12 years of age weighing at least 40 kg.
PAL
